Can Mounjaro Cause Kidney Failure?

Step 1: Understanding what the trial evidence actually shows about kidney function

The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed thousands of adults over 72 weeks on tirzepatide at various doses. Kidney function markers (including estimated glomerular filtration rate and measures of urinary albumin) were broadly preserved or showed modest improvement across the treatment groups, consistent with what you would expect when significant weight is lost and metabolic pressure on the organs reduces.

That is not a blanket safety guarantee for every individual. It is an honest summary of what large-scale data shows at population level. Tirzepatide also holds a licence for type 2 diabetes, and the relationship between blood-sugar control, weight reduction and kidney protection is well-established in that context. What the evidence does not support is the idea that Mounjaro is a nephrotoxic medicine, one that harms the kidneys directly.

Kidney failure specifically was not an outcome observed at higher rates in the tirzepatide arms of those trials. Where kidney events did occur, they were generally in participants with pre-existing conditions that made kidney complications more likely regardless of treatment. The NHS medicines page for tirzepatide does not list kidney failure as a known side effect of Mounjaro.

Step 2: The indirect risk that does exist, dehydration

Here is the part worth paying close attention to. The most common side effects of tirzepatide are gastrointestinal: nausea, vomiting, diarrhoea. For most people these are mild and settle within a week or two of starting or increasing a dose. For a smaller number, they are prolonged or severe enough to cause meaningful fluid loss.

When the body loses fluid faster than it replaces it, kidney filtration can be compromised. This is called acute kidney injury secondary to dehydration, and it is a well-recognised risk with any medicine that causes significant GI illness, not just GLP-1 medicines. The MHRA Yellow Card scheme allows patients and clinicians to report suspected side effects, and the MHRA monitors this kind of secondary risk across the class.

Practical signals to take seriously: if you are vomiting repeatedly and cannot keep fluids down for more than 24 hours, urine output drops noticeably, or urine turns very dark, seek medical attention the same day. Do not wait to see if it improves. This is not alarmism, it is exactly what your prescriber and the Patient Information Leaflet ask you to watch for. If you have questions about alcohol and hydration on treatment, our page on drinking alcohol while on Mounjaro is worth reading alongside this one.

Step 3: Pre-existing kidney disease and what changes if you have it

If you already have chronic kidney disease (at any stage) the picture is more nuanced. Tirzepatide's clinical programme included participants with moderate kidney impairment, and dose adjustments are not automatically required for mild-to-moderate CKD. However, the prescribing decision is more complex, and severe or end-stage kidney disease is a situation where specialist input is required before starting treatment.

A GPhC-registered Independent Prescriber reviews your health history as part of every consultation at a regulated service. They will ask about kidney function, any nephrology follow-up you have, and whether you are taking medicines that interact with kidney clearance. This is not a formality. Our clinical team, led by our Independent Prescriber, treats this kind of assessment as the foundation of safe prescribing, not an afterthought.

If a related concern is whether Mounjaro might contribute to kidney stones rather than kidney failure, that is a separate question with different evidence, you can explore it on our dedicated page about Mounjaro and kidney stones. For a closer look at the broader evidence on whether Mounjaro causes kidney damage, we cover that in detail separately.

Step 4: Who to speak to, and when

If you are worried reading this, that is a reasonable response. Questions about a prescription medicine and your kidneys are not trivial, and the internet tends to produce either unwarranted alarm or unwarranted reassurance. Neither is useful.

The right route is a prescriber who can see your medical history. If you have existing kidney disease and are considering Mounjaro, speak to your GP or nephrologist first. If you are already on treatment and developing symptoms that concern you, contact the clinical team who prescribed it or call NHS 111.

For people who are otherwise in good health and asking this question out of reasonable caution before starting, the evidence is reassuring: the medicine itself is not associated with kidney failure, provided you stay hydrated and act promptly if GI side effects become severe. Mounjaro is also sometimes compared to other medicines in its class when cardiovascular conditions are in the picture, and if you are wondering whether you can take Mounjaro with heart failure, our pages on Mounjaro and heart failure and tirzepatide and heart failure address that angle if relevant to you.

If you are ready to discuss whether Mounjaro is right for your situation, speak to our prescribers via a free consultation, reviewed the same day by a named clinician, not software.